Market Research Logo

Global Neurodegenerative Diseases Market 2015-2019

Global Neurodegenerative Diseases Market 2015-2019

About neurodegenerative diseases

According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely debilitating. They result in progressive degeneration of nerve cells, causing them to die eventually. These diseases cause ataxia and dementia in people, which can have a serious impact on the mental health of patients. Some examples of neurodegenerative diseases are Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, multiple sclerosis, amyotrophic lateral sclerosis, and epilepsy. Huntington’s disease and amyotrophic lateral sclerosis are rare diseases, unlike Alzheimer’s disease and Parkinson’s disease which have a high degree of prevalence.

Technavio's analysts forecast the global neurodegenerative diseases market to grow at a CAGR of 4.77 percent over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global neurodegenerative diseases market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of neurodegenerative diseases. The market includes data from the sales of various drugs used in the treatment of:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global neurodegenerative diseases market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of neurodegenerative diseases are discussed.

Technavio's report, Global Neurodegenerative Diseases Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC; it also covers the global neurodegenerative diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key regions
  • Americas
  • APAC
  • EMEA
Key vendors
  • Biogen Idec
  • Merck Serono
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
  • UCB
Other prominent vendors
  • AB Science
  • Abbvie
  • Acorda Therapeutics
  • Actavis
  • Active Biotech
  • Adamas Pharmaceuticals
  • Akorn
  • Archer Pharmaceuticals
  • Astellas
  • Auspex Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Covis
  • Desitin Arzneimittel
  • Eisai
  • Eli Lilly
  • Endo International
  • F. Hoffmann-La Roche
  • FORUM Pharmaceuticals
  • GlaxoSmithKline
  • Glenmark
  • H. Lundbeck
  • Ipsen
  • Janssen Pharmaceuticals
  • Kyowa Hakko Kirin
  • Mitsubishi Tanabe
  • MorphoSys
  • Newron Pharmaceuticals
  • Omeros
  • Opexa
  • Orion
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Palobiofarma
  • Prana Biotechnology
  • Raptor Pharmaceutical
  • Sanofi
  • Siena Biotech
  • SOM Biotech
  • STADA
  • Takeda Pharmaceutical
  • TauRx Pharmaceuticals
  • US WorldMeds
  • Valeant
  • Zinfandel Pharmaceuticals
  • Market driver
  • High unmet medical needs
  • For a full, detailed list, view our report
  • Market challenge
  • Generic erosion
  • For a full, detailed list, view our report
  • Market trend
  • Reformulation of marketed drugs
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Neurodegenerative Diseases Market 2015-2019

Technavio recognizes the following companies as the key players in Global Neurodegenerative Diseases Market 2015-2019: Biogen, Merck Serono, Novartis, Pfizer, Teva Pharmaceutical and UCB SA

Other Prominent Vendors in the market are: AB Science, Abbvie, Acorda Therapeutics, Actavis, Active Biotech, Adamas, Akorn, Archer, Astellas, Auspex, Bayer, Boehringer Ingelheim, Covis, Desitin Arzneimittel, Eli Lilly, Eisai, Endo International, F. Hoffmann-La Roche, FORUM, GlaxoSmithKline Glenmark, Lundbeck, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Mitsubishi Tanabe, MorphoSys, Newron Pharmaceuticals, Omeros, Opexa, Orion, Otsuka, BioMedica, Palobiofarma, Prana Biotechnology, Raptor, Sanofi, Siena, SOM, STADA, Takeda Pharmaceutical, TauRx Pharmaceuticals, US WorldMeds, Valeant and Zinfandel

Commenting on the report, an analyst from Technavio’s team said: “Reformulation of already marketed drugs is expected to propel market growth during the forecast period. Reformulation is aimed at reducing the side effects of conventional drugs to increase patient compliance and their sales.”

According to the report, high unmet medical needs such as the absence of safe, effective, and affordable treatment options have a negative impact on market growth. In addition, no known cure exists for neurodegenerative diseases and the available drugs only provide symptomatic relief.

Further, the report states that the growing generic erosion of already marketed drugs restricts the growth of the market.

Companies Mentioned

Biogen, Merck Serono, Novartis, Pfizer, Teva Pharmaceutical, UCB SA, AB Science, Abbvie, Acorda Therapeutics, Actavis, Active Biotech, Adamas, Akorn, Archer, Astellas, Auspex, Bayer, Boehringer Ingelheim, Covis, Desitin Arzneimittel, Eli Lilly, Eisai, Endo International, F. Hoffmann-La Roche, FORUM, GlaxoSmithKline Glenmark, Lundbeck, Janssen Pharmaceuticals, Kyowa Hakko Kirin, Mitsubishi Tanabe, MorphoSys, Newron Pharmaceuticals, Omeros, Opexa, Orion, Otsuka, BioMedica, Palobiofarma, Prana Biotechnology, Raptor, Sanofi, Siena, SOM, STADA, Takeda Pharmaceutical, TauRx Pharmaceuticals, US WorldMeds, Valeant, Zinfandel

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Product Profiles
    • Avonex/Rebif
      • Plegridy
      • Tecfidera
      • Tysabri
      • Comtan
      • Stalevo
      • Exelon/Exelon Patch
      • Extavia
      • Gilenya
      • Cerebyx
      • Dilantin-125
      • Lyrica
      • Neurontin
      • Zarontin
      • Azilect
      • Copaxone
      • Keppra/Keppra XR
      • Neupro
      • Vimpat
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global Neurodegenerative Diseases Market 2014-2019 ($ million)
    • Five Forces Analysis
  • Segmentation of Global Neurodegenerative Diseases Market by Type of Disease
    • Table Segmentation of Global Neurodegenerative Diseases Market by Type of Disease
    • Table Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2014
    • Table Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2019
  • Global Multiple Sclerosis Market
    • Multiple Sclerosis: Overview
      • About the Disease
      • Symptoms
      • Etiology
        • Table Etiology of Multiple Sclerosis
      • Epidemiology
      • Economic Burden
    • Market Overview
    • Market Size and Forecast
      • Table Global Multiple Sclerosis Market 2014-2019 ($ million)
    • Multiple Sclerosis Market in US
      • Market Size and Forecast
        • Table Multiple Sclerosis Market in US 2014-2019 ($ million)
  • Global Alzheimer's Disease Market
    • Alzheimer's Disease: Overview
      • About the Disease
      • Dementia
      • Epidemiology and Forecast
        • Table Prevalence of Dementia by Geography 2013, 2030, and 2050 (million)
        • Table Prevalence of Dementia by Geography 2013-2018 (millions)
      • Types of Dementia
        • Table Types of Dementia and Associated Symptoms
        • Table Types of Dementia by Prevalence 2013
      • Global Burden
      • Etiology
      • Cost of Care
        • Table Segmentation of Economic Burden of Alzheimer's Disease and Other Dementias by Geography 2013
        • Table Average Cost of Care for Americans Aged 65 and Above with Alzheimer's Disease and Other Dementias 2013
      • Alzheimer's Disease and Caregiving
        • Table Distribution of Alzheimer's Caregivers by Age 2013
        • Table Projected Prevalence of Dependence 2010 and 2030
    • Market Overview
    • Market Size and Forecast
      • Table Global Alzheimer's Disease Market 2014-2019 ($ million)
  • Global Epilepsy Market
    • Epilepsy: Overview
      • About the Disease
      • Etiology
      • Types of Epilepsy
      • Symptoms
      • Epidemiology
      • Economic Burden
    • Market Overview
    • Market Size and Forecast
      • Table Global Epilepsy Market 2014-2019 ($ million)
    • Epilepsy Market in US
      • Market Size and Forecast
        • Table Epilepsy Market in US 2014-2019 ($ million)
    • Epilepsy Market in Europe
      • Market Size and Forecast
        • Table Epilepsy Market in Europe 2014-2019 ($ million)
    • Epilepsy Market in Japan
      • Market Size and Forecast
        • Table Epilepsy Market in Japan 2014-2019 ($ million)
  • Global Parkinson's Disease Market
    • Parkinson's Disease: Overview
      • About the Disease
      • Symptoms
      • Etiology
      • Epidemiology
      • Economic Burden
    • Market Overview
    • Market Size and Forecast
      • Table Global Parkinson's Disease Market 2014-2019 ($ million)
      • Table Segmentation of Global Parkinson's Disease Market by Country 2014
  • Global Huntington's Disease Market
    • Huntington's Disease: Overview
      • About the Disease
        • Table Snapshot of Disease
      • Symptoms
      • Etiology
      • Prevalence of Huntington's Disease
        • Table Prevalence of Huntington's Disease by Geography 2013
      • Pipeline Portfolio
        • Table Huntington's Disease: Pipeline Portfolio
      • Economic Burden
    • Market Overview
    • Market Size and Forecast
      • Table Global Huntington's Disease Market 2014-2019 ($ million)
  • Global Amyotrophic Lateral Sclerosis Market
    • Amyotrophic Lateral Sclerosis: Overview
      • About the Disease
        • Table Snapshot of Disease
      • Types of Amyotrophic Lateral Sclerosis
      • Etiology and Pathophysiology
      • Symptoms
      • Epidemiology
      • Diagnosis
      • Pipeline Portfolio
        • Table Amyotrophic Lateral Sclerosis: Pipeline Portfolio
    • Market Overview
    • Market Size and Forecast
      • Table Global Amyotrophic Lateral Sclerosis Market 2014-2019 ($ million)
  • Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule
    • Table Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule
    • Biologics
    • Small Molecules
      • Table Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule 2014
  • Segmentation of Global Neurodegenerative Diseases Market by Route of Administration
    • Table Segmentation of Global Neurodegenerative Diseases Market by Route of Administration
    • Oral
    • Parenteral
    • Topical
      • Table Segmentation of Global Neurodegenerative Diseases Market by Route of Administration 2014
  • Geographical Segmentation
    • Table Segmentation of Global Neurodegenerative Diseases Market by Geography 2014
  • Buying Criteria
  • Market Growth Drivers
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Table Global Neurodegenerative Diseases Market Share Analysis 2014
      • Competitive Assessment of Major Drugs
        • Table Major Drugs for Neurodegenerative Diseases by Revenue 2014 ($ million)
        • Table YoY Revenue of Major Drugs for Neurodegenerative Diseases 2011-2014 ($ million)
        • Table Revenue Share of Major Drugs for Neurodegenerative Diseases 2011-2014
      • Biogen Idec
        • Table Biogen Idec: Global Revenue of Products 2011-2014 ($ million)
        • Table Biogen Idec: YoY Global Revenue of Avonex 2011-2014 ($ million)
        • Table Biogen Idec: Revenue of Avonex in US 2011-2014 ($ million)
        • Table Biogen Idec: Revenue of Avonex in ROW 2011-2014 ($ million)
        • Table Biogen Idec: YoY Global Revenue of Tysabri 2011-2014 ($ million)
        • Table Biogen Idec: Revenue of Tysabri in US 2011-2014 ($ million)
        • Table Biogen Idec: Revenue of Tysabri in ROW 2011-2014 ($ million)
        • Table Biogen Idec: YoY Global Revenue of Fampyra 2011-2014 ($ million)
        • Table Biogen Idec: Revenue of Plegridy in US and ROW 2014 ($ million)
        • Table Biogen Idec: Revenue of Tecfidera in US and ROW 2013 and 2014 ($ million)
      • Pfizer
        • Table Pfizer: YoY Global Revenue of Lyrica 2011-2014 ($ million)
        • Table Pfizer: YoY Global Revenue of Neurontin 2011-2013 ($ million)
      • Teva Pharmaceutical
        • Table Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ million)
        • Table Teva Pharmaceutical: Quarterly Revenue of Copaxone 2011-2014 ($ million)
        • Table Teva Pharmaceutical: YoY Global Revenue of Azilect 2011-2014 ($ million)
        • Table Teva Pharmaceutical: Quarterly Revenue of Azilect 2011-2014 ($ million)
      • Novartis
        • Table Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ million)
        • Table Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ million)
        • Table Novartis: YoY Global Revenue of Extavia 2011-2014 ($ million)
        • Table Novartis: YoY Global Revenue of Comtan/Stalevo 2011-2014 ($ million)
        • Table Novartis: Revenue of Comtan/Stalevo in US and ROW 2011-2013 ($ million)
        • Table Novartis: YoY Global Revenue of Exelon/Exelon Patch 2011-2014 ($ million)
        • Table Novartis: Revenue of Exelon/Exelon Patch in US and ROW 2011-2013 ($ million)
      • Merck Serono
        • Table Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ million)
        • Table Merck Serono: Revenue of Rebif in North America 2011-2014 ($ million)
        • Table Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ million)
        • Table Merck Serono: Revenue Share of Rebif by Region 2012-2014
      • UCB
        • Table UCB: YoY Global Revenue of Vimpat 2011-2014 ($ million)
        • Table UCB: YoY Revenue of Vimpat in Europe 2011-2014 ($ million)
        • Table UCB: YoY Revenue of Vimpat in North America 2011-2014 ($ million)
        • Table UCB: YoY Global Revenue of Keppra/Keppra XR 2011-2014 ($ million)
        • Table UCB: YoY Revenue of Keppra/Keppra XR in Europe 2011-2014 ($ million)
        • Table UCB: YoY Revenue of Keppra/Keppra XR in North America 2011-2014 ($ million)
        • Table UCB: YoY Global Revenue of Neupro 2011-2014 ($ million)
        • Table UCB: YoY Revenue of Neupro in Europe 2011-2014 ($ million)
        • Table UCB: YoY Revenue of Neupro in North America 2011-2014 ($ million)
    • Other and Potential Future Prominent Vendors
  • Key Vendor Analysis
    • Biogen Idec
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Biogen Idec: Business Segmentation by Revenue 2013
      • Geographical Segmentation by Revenue 2013
        • Table Biogen Idec: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Merck Serono
      • Key Facts
      • Business Overview
      • Geographical Segmentation by Revenue 2013
        • Table Merck Serono: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Novartis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Novartis AG: Business Segmentation
      • Revenue by Business Segmentation
        • Table Novartis AG: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
      • Sales by Geography
        • Table Novartis AG: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Pfizer
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Pfizer: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Pfizer: Business Segmentation by Revenue 2012 and 2013
      • Geographical Segmentation by Revenue
        • Table Pfizer: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Teva Pharmaceutical
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Teva Pharmaceutical Industries: Business Segmentation
      • Business Segmentation by Revenue 2013
        • Table Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013 ($ million)
      • Sales by Geography
        • Table Teva Pharmaceutical Industries: Sales by Geography 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • UCB
      • Key Facts
      • Business Overview
      • Product Segmentation by Revenue 2013
        • Table UCB: Product Segmentation by Revenue 2013
      • Product Segmentation by Revenue 2012 and 2013
        • Table UCB: Product Segmentation by Revenue 2012 and 2013 ($ million)
      • Geographical Segmentation by Revenue 2013
        • Table UCB: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report